Twist Bioscience

Big news! The first patient has been dosed in Pure Biologics’ exploratory Phase 0 clinical study of PBA-0405, a fully human IgG1 antibody that was discovered using #TwistBiopharmaSolutions’ synthetic antibody phage display libraries! “Solid tumors are historically difficult for drug developers to target and treat. This is the first antibody identified using our Twist Biopharma Solutions Library of Libraries to be tested in patients and it validates the potential of our synthetic antibody libraries to be used to discover novel drug candidates for hard-to-treat cancer indications,” said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “This is one of two of Pure’s candidates discovered using our synthetic antibody libraries and we look forward to seeing their progression.” Read more 👉 https://lnkd.in/gk3V6vFG Twist Bioscience, #antibody, #antibodydiscovery, #DNA

It is with a heavy heart that we share that Garry Merry, a Twister for more than 9 years, left this life today. Many of you had the privilege of working with him directly over the years, learning from his vast and unparalleled knowledge and history of DNA libraries. He educated all of us in this area, shaping the Twist DNA libraries team, providing consistent and (not so) subtle input into the operationalizing of libraries, and leading the biopharma sales team most recently. His jovial laughter and his colorful language complemented his deep industry knowledge, and he will be sincerely missed. We send our condolences to his family, his friends and the wide radius of people he touched deeply. He will be greatly missed.

Powerful molecular tools advance precision cancer research. Our suite of NGS tools support liquid biopsy research, enabling the study of ctDNA patterns. ctDNA—and liquid biopsies by extension—is poised to be a powerful tool in both research and clinical applications. Twist is committed to empowering this work, providing researchers with advanced tools and a team of experts to rely on. Read more about it in our latest blog post below. 👉 https://lnkd.in/gtqMQWkJ Twist Bioscience #DNA #liquidbiopsy #ctDNA #NGS

SUCH important work— practicing to prevent the next pandemic! We’re proud to be part of the sprint to determine how fast #hanta defeating antibodies can be discovered. Twist DNA 🧬 is on its way 📦 to Nashville for next steps! Follow along with the sprint at @VUMC_Vaccines (on Twitter/X). #VVCHantaSprint, Vanderbilt University Medical Center, James Crowe

DNA data storage fans, don’t miss this article by Nina Notman in Chemistry World! With data generation quickly outpacing current storage methods, DNA offers a compact, durable, & low maintenance way of storing our most precious memories. We’re working with the SNIA to develop interoperability and bring DNA data storage from proof of concept to a commonplace archival solution. Twist Bioscience, Emily Leproust, Karin Strauss, Luis Ceze, Robert Grass, DNA Data Storage Alliance Read the article here 👉 https://lnkd.in/gUuyU-NE #DNA #DNADataStorage #datastorage

It was an honor to host Andrea Salinas at our Wilsonville office recently! Twist SVP of Corporate Affairs Angela Bitting and Congresswoman Salinas discussed the positive impacts of biomanufacturing and biotechnology in Oregon and beyond. We are proud to be part of the Wilsonville community working to advance scientific breakthroughs and foster a healthier future. Thank you, Congresswoman, for your support and insightful dialogue!

🦠 Webinar On Demand: Unveiling the Secrets of Predatory Bacteria! 🦠 Discover the fascinating world of Bdellovibrio bacteriovorus, a predatory bacterium that invades and consumes other gram-negative bacteria from within. Join us for an insightful webinar where Dr. Simon Caulton from the University of Birmingham will reveal groundbreaking research on the molecular mechanisms of this unique bacterium. Learn about the newly identified mosaic adhesive trimers (MATs) and their role in bacterial predation. 🔬 In this webinar, you will: - Understand the significance of MATs for B. bacteriovorus. - Explore how these MATs were characterized using advanced structural and biophysical techniques. - Discover why Twist Bioscience Clonal Genes were crucial for this research. - Gain insights into how predatory bacteria bind to prey cells. 📺 WATCH NOW and dive into the world of predatory bacteria: https://lnkd.in/gtRRp8AD

RNA sequencing (RNA-seq) offers a powerful lens into gene expression, complementing DNA sequencing by revealing real-time dynamics of RNA transcripts. This evolving technology is pivotal in identifying diseases, tracing cell identity, and enhancing diagnostics. Explore the current state and applications of RNA-seq in our latest blog! Read it here: https://lnkd.in/gHyt6u-h Twist Bioscience #RNAseq #sequencing #RNA

🎉 Announcing the expansion of our high-throughput antibody portfolio with the launch of a CHO cell line for Twist Express Antibodies! “With the majority of biotherapeutic drugs manufactured in CHO cell lines, expressing small-scale therapeutic antibody candidates in CHO for screening has become a vital first step to ensure successful downstream scale-up. We now provide a comprehensive portfolio of antibody production to further serve the biopharma market by offering both HEK293 with reduced turnaround times enabled by our Express Genes as well as the newly launched CHO cell line for Twist Express Antibodies,” said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By taking on the process of antibody development from sequence to protein, we meet the needs of therapeutic developers who currently make their own antibodies, a costly bottleneck in the discovery pipeline, providing them with a cost-effective, customizable, and scalable offering to support their research.” Twist Bioscience Expands High-throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies: https://lnkd.in/gGh8nv4r #TwistBiopharmaSolutions #antibody #DNA

Announcing the newest addition to our portfolio of synthetic viral controls: RNA control for H5N1 Influenza A! NGS-verified, and covering 99.9% of hemagglutinin (HA) & neuraminidase (NA) genome regions. “As agricultural and infectious disease researchers around the world continue to monitor the spread of H5N1, we continue our unwavering commitment to responding rapidly to threats to public health by providing innovative and critical tools to safeguard our global community and enable monitoring and surveillance as well as vaccine and assay development,” said Emily Leproust, CEO and co-founder of Twist Bioscience. “Our synthetic controls, including the H5N1 Influenza A control, enable broader research access without the need for live viruses. This allows critical work to be conducted in BSL-1 labs, accelerating research and development efforts. Importantly, we maintain biosecurity as a core tenet across all our products and processes. By empowering global research with safe, synthetic tools, we're advancing science while upholding the highest safety standards.” Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A: https://lnkd.in/gEsKJrVN